Literature DB >> 12678248

Development of serum-free media for cell growth and production of viruses/viral vaccines--safety issues of animal products used in serum-free media.

O W Merten1.   

Abstract

The development of media free of serum and animal or human proteins is of utmost importance for increasing the safety of biological produced for therapy and vaccination. The main drawback associated with the use of serum or animal-derived substances for animal cell technology is the potential introduction of contaminants and, in particular, adventitious agents into the process and thus potentially also into the final product. This fact led to an increased effort to replace serum-containing by serum-free media. In most cases, these media are supplemented with purified proteins, peptones, or hydrolysates, mainly of animal or human origin. Although such serum-free media are more defined than serum-containing media, the risk of the introduction of viruses by using animal-derived substances is still present, signifying that only a complete replacement of animal-derived substances by non-animal-derived products leads to a relatively safe serum-free medium. In several examples the potential of serum-free media and media free of any animal-derived component in supporting growth of cell lines of interest for virus production (such as Vero or MDCK) and production of viruses, and, in particular, of influenza virus for vaccine production, are presented and discussed with respect to the classical production processes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12678248

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  14 in total

1.  Introduction to animal cell culture technology-past, present and future.

Authors:  O-W Merten
Journal:  Cytotechnology       Date:  2006-08-03       Impact factor: 2.058

2.  The role of recombinant proteins in the development of serum-free media.

Authors:  Joanne Keenan; Dermot Pearson; Martin Clynes
Journal:  Cytotechnology       Date:  2006-08-05       Impact factor: 2.058

3.  Current Status for High Titre Poxvirus Stock Preparation in CEF Under Serum-Free Medium Conditions: Implication for Vaccine Development.

Authors:  Philippe-Alexandre Gilbert; Lacrimioara Comanita; John Barrett; Andrew Peters; Marta Szabat; Grant McFadden; Gregory A Dekaban
Journal:  Cytotechnology       Date:  2005-06       Impact factor: 2.058

4.  Albumin and mammalian cell culture: implications for biotechnology applications.

Authors:  Geoffrey L Francis
Journal:  Cytotechnology       Date:  2010-04-06       Impact factor: 2.058

Review 5.  Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Crit Care       Date:  2010-04-16       Impact factor: 9.097

Review 6.  Cell-based influenza vaccines: progress to date.

Authors:  Jennifer M Audsley; Gregory A Tannock
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Evaluation of recombinant human transferrin (DeltaFerrin(TM)) as an iron chelator in serum-free media for mammalian cell culture.

Authors:  Joanne Keenan; Dermot Pearson; Lorraine O'Driscoll; Patrick Gammell; Martin Clynes
Journal:  Cytotechnology       Date:  2006-08-03       Impact factor: 2.058

8.  Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium.

Authors:  Alan Yung-Chih Hu; Yu-Fen Tseng; Tsai-Chuan Weng; Chien-Chun Liao; Johnson Wu; Ai-Hsiang Chou; Hsin-Ju Chao; Anna Gu; Janice Chen; Su-Chen Lin; Chia-Hsin Hsiao; Suh-Chin Wu; Pele Chong
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

Review 9.  Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells.

Authors:  Leopold Grillberger; Thomas R Kreil; Sonia Nasr; Manfred Reiter
Journal:  Biotechnol J       Date:  2009-02       Impact factor: 4.677

10.  Influence of cell type and cell culture media on the propagation of foot-and-mouth disease virus with regard to vaccine quality.

Authors:  Veronika Dill; Bernd Hoffmann; Aline Zimmer; Martin Beer; Michael Eschbaumer
Journal:  Virol J       Date:  2018-03-16       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.